To further determine whether USP10 could be a druggable target in these patients, we evaluated the ex vivo antineoplastic effect of pharmacological inhibition of USP10 by Spautin-1 on primary monocytes from 16 patients with CML. The gene discussed is USP10; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.